^Thomas Klabunde, Andreas Evers. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem: A European Journal of Chemical Biology. 2005-5, 6 (5): 876–889 [2019-02-12]. ISSN 1439-4227. PMID 15791686. doi:10.1002/cbic.200400369. （原始内容于2016-06-10）.请检查|date=中的日期值 (帮助)
^David A. Price, Julian Blagg, Lyn Jones, Nigel Greene, Travis Wager. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opinion on Drug Metabolism & Toxicology. 2009-8, 5 (8): 921–931 [2019-02-12]. ISSN 1744-7607. PMID 19519283. doi:10.1517/17425250903042318. （原始内容于2014-11-03）.请检查|date=中的日期值 (帮助)
^Fabrizio De Ponti, Elisabetta Poluzzi, Andrea Cavalli, Maurizio Recanatini, Nicola Montanaro. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety. 2002, 25 (4): 263–286 [2019-02-12]. ISSN 0114-5916. PMID 11994029. doi:10.2165/00002018-200225040-00004. （原始内容于2015-01-02）.
^Maurizio Recanatini, Elisabetta Poluzzi, Matteo Masetti, Andrea Cavalli, Fabrizio De Ponti. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews. 2005-3, 25 (2): 133–166 [2019-02-12]. ISSN 0198-6325. PMID 15389727. doi:10.1002/med.20019. （原始内容于2015-11-28）.请检查|date=中的日期值 (帮助)
^Emanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, Fabrizio De Ponti. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacological Research. 2008-3, 57 (3): 181–195 [2019-02-12]. ISSN 1043-6618. PMID 18329284. doi:10.1016/j.phrs.2008.01.009. （原始内容于2014-11-03）.请检查|date=中的日期值 (帮助)
^Emanuel Raschi, Luisa Ceccarini, Fabrizio De Ponti, Maurizio Recanatini. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opinion on Drug Metabolism & Toxicology. 2009-9, 5 (9): 1005–1021 [2019-02-12]. ISSN 1744-7607. PMID 19572824. doi:10.1517/17425250903055070. （原始内容于2014-11-03）.请检查|date=中的日期值 (帮助)
^Xi-Ping Huang, Vincent Setola, Prem N. Yadav, John A. Allen, Sarah C. Rogan, Bonnie J. Hanson, Chetana Revankar, Matt Robers, Chris Doucette, Bryan L. Roth. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Molecular Pharmacology. 2009-10, 76 (4): 710–722 [2019-02-12]. ISSN 1521-0111. PMC 2769050. PMID 19570945. doi:10.1124/mol.109.058057. （原始内容于2017-07-12）. 引文格式1维护：PMC格式 (link)
^Sanjeev Bhattacharyya, Anthony H. Schapira, Dimitri P. Mikhailidis, Joseph Davar. Drug-induced fibrotic valvular heart disease. Lancet (London, England). 2009-08-15, 374 (9689): 577–585 [2019-02-12]. ISSN 1474-547X. PMID 19683643. doi:10.1016/S0140-6736(09)60252-X. （原始内容于2015-09-19）.
九月 25, 2023
抗靶标, 此條目翻譯品質不佳, 翻譯者可能不熟悉中文或原文語言, 也可能使用了機器翻譯, 請協助翻譯本條目或重新編寫, 并注意避免翻译腔的问题, 明顯拙劣的翻譯請改掛, href, template, html, class, redirect, title, template, href, wikipedia, html, class, redirect, title, wikipedia, 提交刪除, 在药物学中, 一个可以是一个受体, 或者其它生物靶标, 当其和药物作用时会引起不希望的不良反应, 副反应, 对. 此條目翻譯品質不佳 翻譯者可能不熟悉中文或原文語言 也可能使用了機器翻譯 請協助翻譯本條目或重新編寫 并注意避免翻译腔的问题 明顯拙劣的翻譯請改掛 a href Template D html class mw redirect title Template D d a a href Wikipedia CSD html G13 class mw redirect title Wikipedia CSD G13 a 提交刪除 在药物学中 一个抗靶标可以是一个受体 酶 或者其它生物靶标 当其和药物作用时会引起不希望的不良反应 副反应 对于药物研发公司来说 在药物设计和开发过程中确保新药不和大量的被意外发现的抗靶标产生显著活性是至关重要的 1 2 最知名和最显著的抗靶标分别是hERG通道和5 HT2B 受体 会在小范围但不可预知比例的用药人身上分别引发心脏功能的长期问题 QT间期延长综合症和心肌纤维化 这些靶标的发现是由于某些上市药物高频率的特有不良反应 一些具有显著hERG活性的老药依然被警示使用中 大部分被发现是强烈的 5 HT2B激动剂的药物不得不从市场退市 因此 任何先导化合物如果在初期的药物筛选中显示出和这些靶标有较高的亲和力 几乎都会被终止开发 3 4 5 6 7 8 参考文献 编辑 Thomas Klabunde Andreas Evers GPCR antitarget modeling pharmacophore models for biogenic amine binding GPCRs to avoid GPCR mediated side effects Chembiochem A European Journal of Chemical Biology 2005 5 6 5 876 889 2019 02 12 ISSN 1439 4227 PMID 15791686 doi 10 1002 cbic 200400369 原始内容存档于2016 06 10 请检查 date 中的日期值 帮助 David A Price Julian Blagg Lyn Jones Nigel Greene Travis Wager Physicochemical drug properties associated with in vivo toxicological outcomes a review Expert Opinion on Drug Metabolism amp Toxicology 2009 8 5 8 921 931 2019 02 12 ISSN 1744 7607 PMID 19519283 doi 10 1517 17425250903042318 原始内容存档于2014 11 03 请检查 date 中的日期值 帮助 Fabrizio De Ponti Elisabetta Poluzzi Andrea Cavalli Maurizio Recanatini Nicola Montanaro Safety of non antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes an overview Drug Safety 2002 25 4 263 286 2019 02 12 ISSN 0114 5916 PMID 11994029 doi 10 2165 00002018 200225040 00004 原始内容存档于2015 01 02 Maurizio Recanatini Elisabetta Poluzzi Matteo Masetti Andrea Cavalli Fabrizio De Ponti QT prolongation through hERG K channel blockade current knowledge and strategies for the early prediction during drug development Medicinal Research Reviews 2005 3 25 2 133 166 2019 02 12 ISSN 0198 6325 PMID 15389727 doi 10 1002 med 20019 原始内容存档于2015 11 28 请检查 date 中的日期值 帮助 Emanuel Raschi Valentina Vasina Elisabetta Poluzzi Fabrizio De Ponti The hERG K channel target and antitarget strategies in drug development Pharmacological Research 2008 3 57 3 181 195 2019 02 12 ISSN 1043 6618 PMID 18329284 doi 10 1016 j phrs 2008 01 009 原始内容存档于2014 11 03 请检查 date 中的日期值 帮助 Emanuel Raschi Luisa Ceccarini Fabrizio De Ponti Maurizio Recanatini hERG related drug toxicity and models for predicting hERG liability and QT prolongation Expert Opinion on Drug Metabolism amp Toxicology 2009 9 5 9 1005 1021 2019 02 12 ISSN 1744 7607 PMID 19572824 doi 10 1517 17425250903055070 原始内容存档于2014 11 03 请检查 date 中的日期值 帮助 Xi Ping Huang Vincent Setola Prem N Yadav John A Allen Sarah C Rogan Bonnie J Hanson Chetana Revankar Matt Robers Chris Doucette Bryan L Roth Parallel functional activity profiling reveals valvulopathogens are potent 5 hydroxytryptamine 2B receptor agonists implications for drug safety assessment Molecular Pharmacology 2009 10 76 4 710 722 2019 02 12 ISSN 1521 0111 PMC 2769050 nbsp PMID 19570945 doi 10 1124 mol 109 058057 原始内容存档于2017 07 12 引文格式1维护 PMC格式 link Sanjeev Bhattacharyya Anthony H Schapira Dimitri P Mikhailidis Joseph Davar Drug induced fibrotic valvular heart disease Lancet London England 2009 08 15 374 9689 577 585 2019 02 12 ISSN 1474 547X PMID 19683643 doi 10 1016 S0140 6736 09 60252 X 原始内容存档于2015 09 19 取自 https zh wikipedia org w index php title 抗靶标 amp oldid 68627365, 维基百科，wiki，书籍，书籍，图书馆，
